I'm Todd Grolonial from Emory University School of Medicine in Atlanta, Georgia, and I'm going to briefly summarize some of the findings in the triple class refractory session here at the IMS 2023. What we really began talking a little bit about are mechanisms of disease resistance going all the way from the molecular to the clinical aspects of resistant multiple myeloma. And then what I began to talk a little bit about is really focusing on the ways in which we define refractory and that that is now a moving target given that we have so many different types of agents we use in the context of relapsed and refractory myeloma. As you're aware, there is a lot of excitement around bispecific antibodies that target BCMA or GPRC5D, but we also have CAR T cells that target BCMA and eventually GPRC5D. And the big question about sequencing of these agents, combinations of these agents, and how to make each of them better continue to be many of the research questions we're going to ask in the coming few years. I think that amongst our group and our panel, there was tremendous excitement around the idea of ultimately getting patients to deeper long-term responses and perhaps even in the case of relapsed or refractory myeloma, getting potentially to curative endpoints, deep and durable MRD negativity that these are all within our grasp with the kinds of agents we have now and figuring out how to combine them in an effective way really represents the challenge of the next few years.
HealthTree • October 6, 2023